Fierce Biotech

Subscribe to Fierce Biotech feed
Updated: 6 hours 6 min ago

Eisai’s prototype blood test for Alzheimer’s shows links to CSF amyloid in early disease

8 hours 28 min ago
New research from Eisai showed measurable correlations between amyloid biomarkers in the bloodstream and changes in the cerebrospinal fluid, bringing the company a step closer to developing a quick and simple blood test for Alzheimer’s disease.

Looking for Ofev follow-up, Boehringer picks up Bridge Biotherapeutics' IPF med for $50M

9 hours 31 min ago
Nearly five years after lung-scarring med Ofev got the FDA nod, its maker wants to get cracking on a successor. Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics for €45 million ($50 million) upfront.

EuroBiotech Report—Gilead-Galapagos, Alzheimer's fail, AM-Pharma and Abivax

10 hours 34 min ago
In this week's EuroBiotech Report, Gilead and Galapagos ink big deal, Novartis chalks up Alzheimer’s failure and AM-Pharma raises €116 million.

EuroBiotech: More Articles of Note

10 hours 37 min ago
In our EuroBiotech roundup this week, Oryzon posts phase 2 Alzheimer’s data, Mereo eyes fast approval and AC Immune advances Lilly-partnered drug.

Bischofberger-helmed Kronos bags $105M to tackle tough targets

11 hours 37 min ago
Kronos Bio has raised $105 million. The series A sets the Norbert Bischofberger-helmed biotech up to advance efforts to hit historically undruggable targets. 

PPD teams up with Cancer Treatment Centers of America to boost oncology trials

14 hours 5 min ago
PPD is working with Cancer Treatment Centers of America to speed up enrollment into cancer studies.

Gilead CSO, R&D head McHutchison the latest to bid company adieu

Wed, 07/17/2019 - 11:31
Gilead Chief Scientific Officer and R&D chief John McHutchison, M.D., is leaving one year after he took over from the company's longtime R&D lead Norbert Bischofberger, Ph.D.

Musk's Neuralink startup aims to connect brains to the web, starting next year

Wed, 07/17/2019 - 07:36
Elon Musk pulled back the curtain on his brain interface-developing Neuralink in a technology showcase aimed more at recruiting new employees to the secretive company than attesting to its science.

Astellas picks up Frequency's regenerative hearing loss med outside U.S. for $80M

Wed, 07/17/2019 - 06:36
Frequency Therapeutics is licensing its lead hearing loss program to Astellas, which will develop and market the drug outside the U.S., for $80 million upfront. It stands to receive another $545 million in milestones and royalties down the line.

Inovio axes staffers, cancer program to 'sharpen focus,' save cash

Wed, 07/17/2019 - 06:14
A few months after AstraZeneca’s MedImmune unit walked away from some of its R&D work with the biotech, Inovio Pharmaceuticals is cutting 28% of its workforce and swinging the ax on a bladder cancer test.

FDA goes against AdComm votes 22% of the time, study finds

Wed, 07/17/2019 - 05:37
The FDA went against the recommendations of advisory committees 22% of the time between 2008 and 2015, according to a study. 

Immusoft names former Amgen biologics chief as chief scientific officer

Wed, 07/17/2019 - 04:33
Immusoft has named Robert Hayes as chief scientific officer. Hayes, the former head of biologics at Amgen, joins the cell therapy startup as it works to move a treatment for mucopolysaccharidosis type I into clinical testing. 

Reversing the risk of sudden cardiac death with gene therapy

Wed, 07/17/2019 - 03:39
Researchers at Boston Children’s Hospital have created a gene therapy technique that they say might work not just in an inherited form of heart arrhythmia, but also in more common cardiac diseases marked by an irregular heartbeat.

Orum Therapeutics bags $30M to build out its platform to drug the ‘undruggable’

Tue, 07/16/2019 - 19:08
Orum Therapeutics raised $30 million to expand the applications for for its cell-penetrating antibody technology aimed at drugging "undruggable" targets.

Yale, Mayo Clinic tap Biofourmis’ sensors and the new Apple Watch to study digital endpoints for heart disease

Tue, 07/16/2019 - 11:59
Could wearable biosensors change the face of clinical trials and shorten a drug’s regulatory journey? That’s what Yale University and the Mayo Clinic are trying to find out, using biosensors and Biofourmis’ mobile health platform.

GNS Healthcare's AI patient-matching platform nets $23M from Cigna Ventures, Amgen, Celgene

Tue, 07/16/2019 - 11:14
GNS Healthcare has raised $23 million from the venture capital arms of drugmakers and health insurance companies to build out its artificial-intelligence-driven precision medicine platform.

Paragon's new company to carry its AI-powered breast cancer diagnostic buy

Tue, 07/16/2019 - 08:56
Life sciences incubator Paragon Biosciences has built a new portfolio company around its acquisition of the first FDA-cleared artificial intelligence system for diagnosing breast cancer.

On a roll, Genentech inks discovery deals with Skyhawk, Convelo

Tue, 07/16/2019 - 06:38
Genentech started Tuesday with a $1 billion biobucks deal with Sosei Heptares and followed it with two more: one focused on cancer and neurodegenerative diseases with Skyhawk Therapeutics and one on neurological disorders with Convelo Therapeutics.

FDA contributes to hunt for new heart failure endpoints

Tue, 07/16/2019 - 05:41
A collaboration involving the FDA is set to evaluate new endpoints for heart failure clinical trials. The partners will use wearable devices to assess how heart failure patients function and feel after being discharged from hospitals.

Sosei Heptares pens $1B biobucks GPCR pact with Genentech

Mon, 07/15/2019 - 23:56
After spinning out two companies at the start of the year, Sosei Heptares has now inked a new deal with Roche biologics unit Genentech.